University of Kentucky |  UK HealthCare |  News and Events |  Give to Medicine |  About Our College |  Diversity  |   Anonymous Questions 
Gill Heart Institute
home
welcome
General Cardiology Fellowship
Application Information
Rotations
Cardiac Care Unit
Cardiac Catheterization
Electrophysiology
CT/MRI Cardiac Imaging
Echocardiography
Nuclear Cardiology
Adult Congenital Heart Disease
Cardiac Rehabilitation
Clinics
Research
Conferences
Research Fellowship
Interventional Cardiology Fellowship
Electrophysiology Fellowship
Adv CV Imaging Fellowship
Current Fellows
Faculty
Facilities
Events
Lexington, KY
Links
Contact
 Research

Trials Currently Enrolling
TrialInvestigatorsDescription
COMPASS-2 Booth/Wendy Pulmonary arterial hypertension patients treated with sildenafil + placebo vs sildenafil + bosentan
LAPTOP HF Gurley/Rebekah implanted left atrial pressure (LAP) monitor to assist Heart Failure patients in their medical therapy (have had heart failure for at least six months and have been hospitalized at least once in the last year for Heart Failure complications).
PREMIUM Gurley/Mandy Migraine patients (age 18-55yo) randomized to PFO closure vs. medical management
SOLID Campbell/Wendy Darapladib (Lp-PLA2 inhibitor) vs. placebo in acute coronary syndrome (must be enrolled within 30 days of event) to compare incidence of major cardiovascular adverse events.
VEST Elayi/Mandy Patients who present with acute MI and EF =<35% are randomized to LifeVest or standard of care in open label fashion.

RegistryInvestigatorsDescription
ACC/NCDR Lilliana Acute Coronary Syndrom Registry
CHOICE Registry Ziada/Wendy Post-market surveillance to document outcome involving Rx Acculink and Rx Accunet devices and Xact Rapid Exchange, Emboshield BareWire and NAV6 devices.
IPAC Rajagopalan/Wendy Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy
PVD Registry Latif/Lilliana A registry for development and validation of risk adjustment models for clinical outcomes, and appropriateness of percutaneous interventions in vascular patients.

Trials Recruiting Soon
TrialInvestigatorsDescription
EARLY USE OF CRESTOR IN ACS Smyth/Research Nurse Early use of Crestor in ACS: targeting platelet-leukocyte interactions. Patients will receive 40mg Crestor within 8 hours of presentation followed by maintenance dose of 20mg Crestor daily.
LAPLACE TIMI-57 Bailey/Rebekah Tolerability and Efficacy of AMG 145 on LDL-C in Combination with HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects:
  • LDL must be >85 mg/dl
  • Must be able to tolerate subcutaneous injections every 2-4 week for up to 5 months
Last updated 9/1/2011
Comments and Corrections |  An Equal Opportunity University |  Jobs  |  Terms, Conditions & Privacy and Accessibility Statements |  Privacy

© 2012, University of Kentucky College of Medicine, 138 Leader Ave., Lexington, Kentucky, USA 40506-9983
Clinical Questions: (859) 257-1000 · College of Medicine Questions: (859) 323-6582
Page last updated Monday, May 14th, 2012